Paul Flechsig1,2, Clemens Kratochwil3, Arne Warth4,2, Daniel Rath3, Viktoria Eichwald5, Peter E Huber6, Hans-Ulrich Kauczor1,2, Uwe Haberkorn3,7, Frederik L Giesel8,9. 1. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany. 2. Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany. 3. Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany. 4. Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 5. Core Facility Small Animal Imaging, German Cancer Research Center, Heidelberg, Germany. 6. Molecular Radiation Oncology, German Cancer Research Center and University Hospital Center Heidelberg, Heidelberg, Germany. 7. Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. 8. Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany. frederik@egiesel.com. 9. Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. frederik@egiesel.com.
Abstract
PURPOSE: The demand to optimize multidisciplinary treatment strategies in patients with benign and malignant diseases of the lung and other organs has led to the increased need of mechanistic proof-of-concept studies in preclinical small animal models using new non-invasive imaging methods. Therefore, we evaluated the role of microPET and microCT for mediastinal lymph node staging in an orthotopic lung cancer model in rats. PROCEDURES: Human lung cancer cells (NCI-H460) were injected transthoracically in nude rats (NIH-RNU). After 2 weeks of tumour growth, animals underwent multiphase contrast-enhanced microCT using ExiTron nano 12000 as a contrast agent and dynamic microPET using the tracer 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG). Thereafter, animals were sacrificed for histological analysis. RESULTS: Late phase micro X-ray computed tomography (microCT) revealed the best delineation of lymph node metastases, as compared to earlier scans. In terms of an increased [(18)F]FDG uptake over time, dynamic micro positron emission tomography (microPET) delineated lymph node metastases and enabled metabolic examinations of the induced lung cancer metastases. CONCLUSION: The combination of contrast-enhanced microCT and dynamic microPET is feasible in rats for the visualization of mediastinal lymph node metastases.
PURPOSE: The demand to optimize multidisciplinary treatment strategies in patients with benign and malignant diseases of the lung and other organs has led to the increased need of mechanistic proof-of-concept studies in preclinical small animal models using new non-invasive imaging methods. Therefore, we evaluated the role of microPET and microCT for mediastinal lymph node staging in an orthotopic lung cancer model in rats. PROCEDURES: Humanlung cancer cells (NCI-H460) were injected transthoracically in nude rats (NIH-RNU). After 2 weeks of tumour growth, animals underwent multiphase contrast-enhanced microCT using ExiTron nano 12000 as a contrast agent and dynamic microPET using the tracer 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG). Thereafter, animals were sacrificed for histological analysis. RESULTS: Late phase micro X-ray computed tomography (microCT) revealed the best delineation of lymph node metastases, as compared to earlier scans. In terms of an increased [(18)F]FDG uptake over time, dynamic micro positron emission tomography (microPET) delineated lymph node metastases and enabled metabolic examinations of the induced lung cancer metastases. CONCLUSION: The combination of contrast-enhanced microCT and dynamic microPET is feasible in rats for the visualization of mediastinal lymph node metastases.
Entities:
Keywords:
Computed tomography; Lung cancer; Orthotopic lung cancer model; [18F]FDG/PET-CT
Authors: Debabrata Saha; Linda Watkins; Yi Yin; Philip Thorpe; Michael D Story; Kwang Song; Pavithra Raghavan; Robert Timmerman; Benjamin Chen; John D Minna; Timothy D Solberg Journal: Radiat Res Date: 2010-07 Impact factor: 2.841
Authors: Claude Nahmias; Wahid T Hanna; Lindi M Wahl; Misty J Long; Karl F Hubner; David W Townsend Journal: J Nucl Med Date: 2007-05 Impact factor: 10.057
Authors: U Haberkorn; L G Strauss; A Dimitrakopoulou; E Seiffert; F Oberdorfer; S Ziegler; C Reisser; J Doll; F Helus; G van Kaick Journal: J Nucl Med Date: 1993-01 Impact factor: 10.057
Authors: Uwe Haberkorn; Johannes Hoffend; Kerstin Schmidt; Annette Altmann; Gabriel A Bonaterra; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Michael Eisenhut; Ralf Kinscherf Journal: Eur J Nucl Med Mol Imaging Date: 2007-08-15 Impact factor: 9.236